How to avoid being a victim of a pharmacist fraud
In November, The Washington Post reported that Accredo Pharmacy in Alexandria, Virginia, had become the latest pharmacy to pay a $1.9 million fine for allegedly selling prescription opioids to patients without their permission.
Since then, several other pharmacies in Maryland and Virginia have also come under scrutiny for their practices, including Walgreens and Rite Aid.
According to The Washington Times, Accredo was not the only pharmacy to be caught in the scheme.
A number of pharmacies in Texas, Arizona, New York, and Florida have also been fined, including a pharmacy in Fort Lauderdale that was recently fined $2 million for allegedly illegally selling drugs without prescriptions.
Accredo is not alone.
As recently as April, New Jersey-based Rite Aid was fined $6.8 million for a similar scheme.
Pharmacists across the country have been caught selling drugs to patients for decades.
According a recent report by the Center for Responsive Politics, about 15 million prescriptions are filled every year in the United States, including 5 million to 6 million for opioids.
However, there is no federal regulation or law requiring pharmacies to obtain written consent for patients to receive prescriptions, nor does it exist to prevent a pharmacy from billing patients for services without their authorization.
The DEA has also been criticized for its lack of enforcement of the law, which makes it hard for states to enforce laws that require pharmacies to make reasonable efforts to prevent fraud.
While the DEA has made strides to protect the health and safety of its patients and employees, it has also had its share of controversies and delays in enforcing the law.
One of the biggest problems is the inability of states to make drug manufacturers liable for fraud.
When the drug manufacturers themselves are not responsible, it’s often the pharmacy that’s being charged.
That’s why the FDA has taken action to require drug makers to provide a prescription-monitoring program that includes monitoring for suspicious sales of prescription opioids.
As a result of the drug-maker-sue provisions, the FDA is now requiring all pharmacies to have an independent, third-party, third party monitor.
The government also wants pharmacies to keep records of all sales and prescriptions made for any drug, and it has been asking pharmacists to report suspicious sales to the DEA.
But the DEA is also taking a hard line with states that do not have such programs.
For example, the agency has said that pharmacies are not required to follow state law that requires prescription-verification programs for prescription opioids, and that it will not enforce any state law prohibiting a pharmacy’s receipt of a prescription from a patient without a prescription.
For more than a decade, the Drug Enforcement Administration has sought to crack down on pharmacies that allegedly make prescriptions to patients who are not authorized to receive the drugs, and the Department of Justice has also taken enforcement action against pharmacies that are found to be selling prescription drugs without authorization.
For instance, in 2006, the DEA began to take enforcement action to prosecute pharmacy executives who sold prescriptions to people who were not eligible to get them.
As of last year, the number of cases the DEA brought against pharmacies for making prescriptions without authorization had grown to 8,746.
Last year, DEA Enforcement Division Chief John Carlin also announced that he would be stepping down in the coming months.
In April, the Department announced that the DEA would launch an Inspector General investigation into Accredo, noting that the pharmacy had been involved in over 100 similar instances since 2006.
Accreditation programs for pharmacies have also recently been in the news.
In September, the American Pharmacists Association (APA) voted to end its accreditation of Accredo for a number of reasons.
According the APA, Accred, which has been operating in Virginia for more than 30 years, failed to comply with the agency’s requirements for drug-prescription pharmacies and also failed to meet the agency standards for providing quality services.
Accred has been subject to numerous complaints over the years about inadequate quality control and lack of training for employees.
The APA also stated that Accred “did not follow the APSA Drug Prescription Program Requirements, which include the need to have a written plan for the provision of drugs.”
According to the APAA, Accreditation is also not required for Accred to participate in the Drug Prescribing Partnership, a national initiative to strengthen drug prescribing and education programs for healthcare professionals.
The Drug Prescriptions Partnership is aimed at encouraging the adoption of quality drug prescribing practices.
AccRED was also involved in a separate lawsuit, in which the APPA sued Accred for failing to properly record its records and conduct quality control for the sale of prescription painkillers.
The suit alleges that AccRED failed to conduct quality controls on its drug prescribing records and conducted no follow-up investigations.
Accredd also failed in its obligation to adequately investigate and report on suspicious sales, including sales that occurred after the prescription was filled.
AccRed did not conduct an investigation on suspicious prescriptions until March 2015, nearly a year after the first complaint was filed.